Beroni Group announced that it has signed a Memorandum of Understanding with tella, Inc. (tella) to collaborate in the field of immunotherapy for cancer treatment. tella is a Japanese company contributing to the advancement of cancer therapy through the research and development of cancer vaccines. tella's dendritic cell vaccine therapy aims to increase the dendritic cell population and strengthen the attacking system against cancers.

In 2019, tella's dendritic cell vaccine therapy has been provided to approximately 12,200 patients in 28 medical institutions around Japan. Beroni and tella acknowledge that the resources possessed by each party and their respective affiliates such as technologies, knowledge and networks, are of high value to each other. In this context, they intend to build strategic partnerships in the field of immunotherapy for cancer treatment, such as conducting clinical trials in dendritic cell vaccine and gamma delta T cells in both Japan and China, crossing shareholding by both parties, technical exchange between both parties and other strategic developments.